MAIA Biotechnology, Inc.

Item 1. Legal Proceedings

On April 22, 2026, H.C. Wainwright & Co., LLC (“Wainwright”) filed complaint in the Supreme Court of the State of New York, County of New York with respect to an action for damages under New York law for breach of contract arising from the Company’s breach of a right of first refusal provision set forth in the parties’ engagement agreement, arising from a March 2026 offering of securities by the Company (the “Wainwright Action”). Wainwright seeks the amount of compensation they could have received as underwriter in the March 2026 offering being (i) $2,310,616.88 in cash and (ii) warrants to purchase 1,540,411 shares of our common stock as an exercise price of $1.875 per share. On June 26, 2026, the Company filed a notice of motion for dismissal. At this early stage in the proceedings, the Company is unable to make any prediction regarding the outcome of the Wainwright Action.

From time to time, we may be involved in legal proceedings or subject to claims in the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.